Compare SUVEN LIFE with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs STERLING BIOTECH - Comparison Results

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES STERLING BIOTECH SUVEN LIFESCIENCES/
STERLING BIOTECH
 
P/E (TTM) x 19.9 -0.4 - View Chart
P/BV x 4.0 0.0 28,312.6% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 SUVEN LIFESCIENCES   STERLING BIOTECH
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
STERLING BIOTECH
Dec-13
SUVEN LIFESCIENCES/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs33811 3,216.2%   
Low Rs1693 4,982.4%   
Sales per share (Unadj.) Rs52.126.8 194.5%  
Earnings per share (Unadj.) Rs6.8-15.0 -45.7%  
Cash flow per share (Unadj.) Rs8.6-5.5 -156.9%  
Dividends per share (Unadj.) Rs1.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs65.354.9 119.0%  
Shares outstanding (eoy) m127.28267.87 47.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.90.3 1,876.0%   
Avg P/E ratio x37.1-0.5 -7,988.3%  
P/CF ratio (eoy) x29.6-1.3 -2,325.4%  
Price / Book Value ratio x3.90.1 3,066.7%  
Dividend payout %22.00-   
Avg Mkt Cap Rs m32,2721,862 1,733.5%   
No. of employees `0001.11.4 79.9%   
Total wages/salary Rs m661547 120.9%   
Avg. sales/employee Rs Th6,132.25,303.3 115.6%   
Avg. wages/employee Rs Th611.1403.8 151.3%   
Avg. net profit/employee Rs Th803.5-2,959.0 -27.2%   
INCOME DATA
Net Sales Rs m6,6357,181 92.4%  
Other income Rs m24243 568.8%   
Total revenues Rs m6,8777,223 95.2%   
Gross profit Rs m1,604947 169.4%  
Depreciation Rs m2212,543 8.7%   
Interest Rs m384,377 0.9%   
Profit before tax Rs m1,587-5,931 -26.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m718-1,924 -37.3%   
Profit after tax Rs m869-4,007 -21.7%  
Gross profit margin %24.213.2 183.4%  
Effective tax rate %45.232.4 139.4%   
Net profit margin %13.1-55.8 -23.5%  
BALANCE SHEET DATA
Current assets Rs m6,23214,335 43.5%   
Current liabilities Rs m1,49049,809 3.0%   
Net working cap to sales %71.5-494.0 -14.5%  
Current ratio x4.20.3 1,453.3%  
Inventory Days Days86403 21.4%  
Debtors Days Days83171 48.4%  
Net fixed assets Rs m4,04355,432 7.3%   
Share capital Rs m127268 47.5%   
"Free" reserves Rs m8,18313,935 58.7%   
Net worth Rs m8,31014,701 56.5%   
Long term debt Rs m189,478 0.2%   
Total assets Rs m10,38973,988 14.0%  
Interest coverage x43.1-0.4 -12,143.9%   
Debt to equity ratio x00.6 0.3%  
Sales to assets ratio x0.60.1 658.1%   
Return on assets %8.70.5 1,743.2%  
Return on equity %10.5-27.3 -38.4%  
Return on capital %19.5-6.4 -303.7%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m5,6221,860 302.3%   
Fx outflow Rs m1,79925 7,229.5%   
Net fx Rs m3,8221,835 208.3%   
CASH FLOW
From Operations Rs m3561,719 20.7%  
From Investments Rs m-279-3,148 8.8%  
From Financial Activity Rs m-2251,426 -15.8%  
Net Cashflow Rs m-148-3 4,358.8%  

Share Holding

Indian Promoters % 63.4 33.9 187.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.0 -  
FIIs % 0.0 9.9 -  
ADR/GDR % 0.0 16.9 -  
Free float % 36.5 39.3 92.9%  
Shareholders   37,287 21,482 173.6%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  ABBOTT INDIA  

Compare SUVEN LIFESCIENCES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

SUVEN LIFESCIENCES Surges by 6%; BSE HEALTHCARE Index Up 0.5% (Market Updates)

Oct 22, 2019 | Updated on Oct 22, 2019

SUVEN LIFESCIENCES share price has surged by 6% and its current market price is Rs 284. The BSE HEALTHCARE is up by 0.5%. The top gainers in the BSE HEALTHCARE Index is SUVEN LIFESCIENCES (up 5.7%). The top losers are AJANTA PHARMA and CADILA HEALTHCARE .

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Oct 22, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS